media – Page 6 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

The 11th batch of centralized drug procurement has been launched; Zhongsheng Pharmaceutical acquires Lixin | 21 Health Daily

The 11th batch of centralized drug procurement work has been launched On July 15th, the National Healthcare Security Administration announced that the 11th batch of national organized drug centralized procurement work has been launched recently. After three-stage screening, 55 varieties have been included in the scope of the 11th batch of centralized procurement reporting. The person in charge of the relevant department of the National Medical Insurance Administration introduced that the 11th batch of centralized procurement of drugs organized by the state has completed the selection of the intended procurement varieties, and the reporting work for medical institutions will soon be carried out. The overall procurement rules will adhere to the principles of “stabilizing clinical practice, ensuring quality, preventing bid rigging, and combating internal competition”. Adhere to the principle of “centralized procurement of non new drugs and non centralized procurement of new drugs”, and scientifically determine the procurement varieties. ...
- Source: drugdu
- 96
- July 17, 2025
GLP-1/GIP dual receptor agonist HRS9531 obtains positive top-line results in China Phase III weight loss study

On July 15, Hengrui Medicine and Kailera Therapeutics of the United States jointly announced that the Phase III clinical trial (HRS9531-301) of HRS9531 injection, a dual receptor agonist of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), for the treatment of obese or overweight subjects in China has obtained positive top-line results. Compared with placebo, all dose groups of HRS9531 (2mg, 4mg, 6mg) achieved superiority in the co-primary endpoints and all key secondary endpoints. Hengrui Medicine said that the company plans to submit a new drug application (NDA) for HRS9531 injection for long-term weight management in China in the near future, and Kailera Therapeutics is promoting the global clinical development of HRS9531 (KAI-9531). According to Hengrui Medicine , HRS9531 is aA self-developed GLP-1/GIP dual receptor agonist. To date, HRS9531 has been tested in a number of clinical trials. HRS9531-301 is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study ...
- Source: drugdu
- 85
- July 17, 2025
Domestic marketing authorization application for Perindopril Amlodipine Tablets approved

Lisheng PharmaceuticalOn the evening of July 15, it was announced that two specifications of Perindopril Amlodipine Tablets developed by Lisheng Pharmaceutical have recently been approved for marketing by the National Medical Products Administration. Perindopril Amlodipine Tablets (I) is the second in China and Perindopril Amlodipine Tablets (III) is the fourth in China. Generic drugs approved according to the new registration classification of chemical drugs are deemed to have passed the consistency evaluation. The specification of Perindopril Amlodipine Tablets (I) is 5 mg of perindopril arginine and 5 mg of amlodipine besylate per tablet (calculated as C20H25ClN2O5). Lisheng Pharmaceutical is the first company in China to obtain approval for generic drugs of this specification. The approval of Perindopril Amlodipine Tablets will further enrich the company’s product structure and help expand the company’s business areas. In January 2024, Lisheng Pharmaceutical submitted an application for registration and marketing authorization of Perindopril Amlodipine Tablets ...
- Source: drugdu
- 37
- July 17, 2025
New study shows that a compound containing NMN can enhance anti-cancer immunity

Recently, scientist Vollmer and his colleagues published a study in the International Journal of Molecular Sciences, proving that taking a group of anti-aging compounds can enhance immunity, which is a key protective factor against aging. The mixture of compounds tested in the study included nano-filtered colostrum, egg yolk extract, NMN, quercetin, α-ketoglutaric acid, white mushroom and celery seed extract—collectively known as AgePro. In addition, immune cell-induced cancer cell killing was enhanced in adults aged 23 to 89, indicating that these compounds are effective at all ages. Importantly, AgePro does not activate immune cells in the absence of cancer cells, indicating that it is safe to take AgePro and the risk of autoimmunity is low. These findings suggest that a mixture of these compounds can safely enhance anti-cancer immunity, that is, it does not activate immune cells against healthy cells. AgePro enhances immune cell-induced cancer cell death Since decreased immunity is ...
- Source: drugdu
- 42
- July 17, 2025
Bayer wins the “world’s first”

Recently, the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom officially approved the marketing of elinzanetant, a non-hormonal drug developed by Bayer, for the treatment of moderate to severe vasomotor symptoms associated with menopause (such as hot flashes and night sweats). This approval is a milestone, and elinzanetant has become the world’s first neurokinin-1 and -3 (NK-1,3) dual receptor antagonist approved for this indication. Menopause is a natural stage in many women’s lives, but the symptoms that come with it, such as hot flashes and night sweats, bring a lot of inconvenience to their lives. Traditionally, hormone replacement therapy has been the main treatment, but many women are unable or unwilling to take this treatment due to its potential side effects. The emergence of elinzanetant brings new hope to these women. The drug effectively relieves menopausal hot flashes by inhibiting overactive KNDy neurons in the hypothalamus (which ...
- Source: drugdu
- 43
- July 17, 2025
Shenzhen International Exhibition of Laboratory Medicine and In Vitro Diagnostic Reagents (CEIVD)

Organiser: China Healthcare Industry Association, Chinese Medical Exchange Association Time：December 10 – December 12, 2025 address：No. 1 Zhancheng Road, Fuhai Sub-district, Bao’an District, Shenzhen City, Guangdong Province Exhibition hall：Shenzhen World Exhibition & Convention Center (Bao’an New Venue) Product range: Clinical Laboratory Equipment: Biochemical analyzers, immunoassay analyzers, bacterial analyzers, urine analyzers, microbiological analyzers, electrolyte analyzers, hematology analyzers, hemodialysis machines, microplate readers, chromatographs, PCR instruments, etc. Clinical Laboratory Reagents: In vitro diagnostic reagents, rapid diagnostic reagents, electrolyte reagents, hematology reagents, blood coagulation reagents, blood typing test kits, lipid reagents, biochemical reagents, chemiluminescent reagents, dry chemistry test strips, reagents for chlamydia detection, methamphetamine detection reagents, protein detection reagents, infectious disease detection reagents, tumor marker reagents, human gene detection reagents, immunohistochemistry and human tissue cell reagents, biochips, vitamin assay reagents, cell and tissue chemical staining agents, autoimmune diagnostic reagents, microbiological testing reagents, and other diagnostic reagents. Blood Transfusion-related Products: Blood collection and supply ...
- Source: drugdu
- 106
- July 17, 2025
Danish Study

Early childhood vaccines containing aluminum are not linked to a higher risk for developing autoimmune, allergic, or neurodevelopmental disorders, according to a nationwide study of Danish children. The study, which looked at more than 1.2 million children over 24 years, provides additional evidence supporting the safety of aluminum-adsorbed vaccines, said senior author Anders Peter Hviid, MSc, DMSc, of Statens Serum Institut in Copenhagen. “Our results provide robust evidence to help parents make the right decisions about the health of their children and for clinicians and public health officials to communicate about the excellent safety of the childhood vaccines,” Hviid told Medscape Medical News. “It’s understandable that more and more parents are concerned about vaccine safety, given the mixed messages that they receive currently. We hope that our study can help settle the issue on this particular concern.” Aluminum adjuvants have been used in non-live vaccines to boost immune response for ...
- Source: drugdu
- 70
- July 16, 2025
Household Mold Can Trigger Lung Disease

By Dennis Thompson HealthDay ReporterMONDAY, July 14, 2025 (HealthDay News) — Household mold can be a significant trigger for a rare but potentially debilitating lung disease that can cause permanent breathing problems, a new study says. Mold appears to be the primary cause for nearly a quarter (23%) of 231 cases of hypersensitivity pneumonitis (HP) treated at the University of Texas Southwestern Medical Center in Dallas, researchers report in the journal PLOS One. It’s the largest study to date linking home mold exposure to HP, researchers said. HP is an interstitial lung disease, a group of diseases that irritate, inflame or scar lung tissue. “This case series is important because it links home mold exposure with the development of hypersensitivity pneumonitis, which informs our efforts to diagnose and treat interstitial lung diseases,” lead author Dr. Traci Adams, an assistant professor of internal medicine at UT Southwestern, said in a news ...
- Source: drugdu
- 48
- July 16, 2025
U.S. clinical study of ASC47 combined with semaglutide for the treatment of obesity completes dosing of subjects

July 15, Ascletis Pharmaceuticals-B (01672.HK) announced on the Hong Kong Stock Exchange that the randomized, double-blind, placebo-controlled study (ASC47-103 study, NCT06972992) to evaluate the safety, tolerability and preliminary efficacy of a single subcutaneous injection of ultra-long-acting ASC47 combined with semaglutide in obese subjects without type 2 diabetes on day 29 has recently completed dosing of all 28 subjects. The enrollment of the 28 subjects was completed quickly within two months. “The rapid progress of ASC47 clinical enrollment highlights the industry’s strong interest in weight-loss new therapies and the potential benefits of combination therapy,” said Dr. Jinzi Wu, Founder, Chairman and CEO of Ascletis. “The trial is progressing steadily as planned and is expected to obtain its top-line data in the fourth quarter of 2025.” https://finance.eastmoney.com/a/202507153456982312.html
- Source: drugdu
- 41
- July 16, 2025
Mabwell Biopharma licenses two denosumab injections to Philippine pharmaceutical company UNILAB

On July 14, Mabwell Biopharma announced that the company’s two denosumab injections 9MW0311 (Prolia® biosimilar, domestic trade name: Mylishu®) and 9MW0321 (Xgeva® biosimilar, domestic trade name: Mabwell®) signed a licensing and commercialization agreement with the Philippine pharmaceutical company UNILAB, INC. (hereinafter referred to as “UNILAB”). According to the agreement, UNILAB will be responsible for the registration and sales of the two products in the Philippines, and Mabwell Biopharma will be responsible for the development, production and commercial supply of the products. It is reported that UNILAB is a leading pharmaceutical company in the Philippines, committed to the sales and promotion of high-quality new drugs in the Philippine market. According to IQVIA data, UNILAB ranks first in the pharmaceutical industry of the Association of Southeast Asian Nations with its production, registration and marketing capabilities. In August 2023, Mabwell Biopharma and UNILAB reached a strategic cooperation on adalimumab biosimilars, and the relevant ...
- Source: drugdu
- 50
- July 16, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.